| abstract |
We disclose an isoform specific antagonist of PAK kinase, which is preferably a molecule capable of modulating an interaction between Nck and a PAK isoform. In particular αPAK, βPAK and ϜPAK specific inhibitors are disclosed. We also disclose methods of treatment of diseases preferably characterised by a defect in nerve regeneration, comprising modulating an activity of a PAK kinase isoform, preferably αPAK kinase or ϜPAK kinase, or both. |